[
  {
    "ts": null,
    "headline": "Doximity Stock Falls Despite Q3 Earnings & Revenues Beat Estimates",
    "summary": "DOCS beats Q3 EPS and revenue estimates, but shares plunge 38.5% after hours as margins contract and FY26 revenue guidance is lowered.",
    "url": "https://finnhub.io/api/news?id=9ff064596e7c589babbaf8481e01fa1ceb8dae15af14f55d297acb17d4338e71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770402120,
      "headline": "Doximity Stock Falls Despite Q3 Earnings & Revenues Beat Estimates",
      "id": 138378364,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "DOCS beats Q3 EPS and revenue estimates, but shares plunge 38.5% after hours as margins contract and FY26 revenue guidance is lowered.",
      "url": "https://finnhub.io/api/news?id=9ff064596e7c589babbaf8481e01fa1ceb8dae15af14f55d297acb17d4338e71"
    }
  },
  {
    "ts": null,
    "headline": "Here's How Quest Diagnostics Is Placed Ahead of Q4 Earnings",
    "summary": "DGX heads into Q4 earnings with expected revenue and EPS growth, DIS momentum, and benefits from Fresenius assets and consumer testing.",
    "url": "https://finnhub.io/api/news?id=49057bd7c58714e8c7669a74fdd79ceed424b0244c0f7f566b37670c4ff50b02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770389100,
      "headline": "Here's How Quest Diagnostics Is Placed Ahead of Q4 Earnings",
      "id": 138377007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "DGX heads into Q4 earnings with expected revenue and EPS growth, DIS momentum, and benefits from Fresenius assets and consumer testing.",
      "url": "https://finnhub.io/api/news?id=49057bd7c58714e8c7669a74fdd79ceed424b0244c0f7f566b37670c4ff50b02"
    }
  },
  {
    "ts": null,
    "headline": "Cardinal Health Q2 Earnings Call Highlights",
    "summary": "Cardinal Health (NYSE:CAH) reported fiscal second-quarter 2026 results that management described as “another excellent quarter,” citing broad-based momentum across the portfolio and double-digit profit growth in each of its five operating segments. Executives also raised full-year earnings guidance",
    "url": "https://finnhub.io/api/news?id=62db20e3ce01d2f4be633b7f7e5b597fe1bd59ede4c77cd7806fde06762b3db8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770370048,
      "headline": "Cardinal Health Q2 Earnings Call Highlights",
      "id": 138373011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Cardinal Health (NYSE:CAH) reported fiscal second-quarter 2026 results that management described as “another excellent quarter,” citing broad-based momentum across the portfolio and double-digit profit growth in each of its five operating segments. Executives also raised full-year earnings guidance",
      "url": "https://finnhub.io/api/news?id=62db20e3ce01d2f4be633b7f7e5b597fe1bd59ede4c77cd7806fde06762b3db8"
    }
  },
  {
    "ts": null,
    "headline": "Is Cardinal Health (CAH) Pricing Reflect Its Surge And Role In The Healthcare Supply Chain",
    "summary": "If you are looking at Cardinal Health and wondering whether the recent run has left the stock overpriced or still attractive, this article will walk through what the current price might be implying. The share price sits at US$227.18, with returns of 7.6% over 7 days, 9.0% over 30 days, 10.4% year to date and 81.1% over 1 year, and very large gains over 3 and 5 years. This naturally raises questions about how much value is already reflected. Recent news flow around Cardinal Health has focused...",
    "url": "https://finnhub.io/api/news?id=16a9fe228298d71a75a8c2ddd36ce3c0e585eb32de9bac7574ba34a166a4bca4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770365333,
      "headline": "Is Cardinal Health (CAH) Pricing Reflect Its Surge And Role In The Healthcare Supply Chain",
      "id": 138373012,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "If you are looking at Cardinal Health and wondering whether the recent run has left the stock overpriced or still attractive, this article will walk through what the current price might be implying. The share price sits at US$227.18, with returns of 7.6% over 7 days, 9.0% over 30 days, 10.4% year to date and 81.1% over 1 year, and very large gains over 3 and 5 years. This naturally raises questions about how much value is already reflected. Recent news flow around Cardinal Health has focused...",
      "url": "https://finnhub.io/api/news?id=16a9fe228298d71a75a8c2ddd36ce3c0e585eb32de9bac7574ba34a166a4bca4"
    }
  },
  {
    "ts": null,
    "headline": "CAH Q4 Deep Dive: Specialty and Growth Segments Drive Outperformance and Upgraded Outlook",
    "summary": "Healthcare distributor and services company Cardinal Health (NYSE:CAH) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 18.8% year on year to $65.63 billion. Its non-GAAP profit of $2.63 per share was 11.2% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=414bd384dc321a45bc4a9ccb520e0613898d4f7645a2f0b2e73671adcc099215",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770356058,
      "headline": "CAH Q4 Deep Dive: Specialty and Growth Segments Drive Outperformance and Upgraded Outlook",
      "id": 138373673,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Healthcare distributor and services company Cardinal Health (NYSE:CAH) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 18.8% year on year to $65.63 billion. Its non-GAAP profit of $2.63 per share was 11.2% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=414bd384dc321a45bc4a9ccb520e0613898d4f7645a2f0b2e73671adcc099215"
    }
  }
]